Trial intelligence / Profile preview

Tripterygium wilfordii polyglycosides plus adalimumab versus methotrexate plus adalimumab in rheumatoid arthritis

ChiCTR2100050865Phase 4Recruiting

Sponsor
The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
Start
Jun 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label trial of tripterygium wilfordii polyglycosides, adalimumab and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine. Primary endpoints: Low disease activity rate and Clinical remission rate. Started Jun 2020; status: recruiting.

02

Drugs

tripterygium wilfordii polyglycosidesadalimumabmethotrexate
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on ChiCTR2100050865.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2100050865.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call